Transcript Биофармацевтический кластер Новосибирской области

Biotechnology Park
of The Siberian Science Town
KOLTSOVO
Novosibirsk
2013
Preconditions of a cluster ’s
development
• Novosibirsk region is located in the heart of Russia. At the crossing of major
transport routes connecting Europe and Asia which contributed to the
concentration of population, industrial enterprises, scientific and education
institutions, infrastructure at its territory in a record-breaking time.
• The modern sectors of economy such as telecommunications, information
technologies, trade, banking and financial services have formed there
rapidly in recent years.
• The unique concentration of scientific and educational institutions and
innovative companies, diversified economy, business development and
social infrastructure determine the main directions of the Novosibirsk region
development
• The economic policy of the government of the Novosibirsk region is aimed at
stimulating investment activity primarily focused on the knowledge-intensive
and high-tech production.
2
Scientific center
•
•
•
o
o
o
o
o
o
Novosibirsk is one of the leading Russian regions on the
level of development of medicine and skill level of medical
personnel
The Novosibirsk region has already adopted and
implemented the system of human resources training
required for development of the biopharmaceutical industry.
The following institutions and organizations work in the
Novosibirsk region:
Siberian branch of Russian Academy of Science
Siberian branch of Russian Academy of Medical Science
Siberian branch of Russian Academy of AgriculturalScience
State Research Center of Virology and Biotechnology
VECTOR
More than 60 scientific and research, decignengineering and
design institutes.
More than 100 large and 1 500 small business related to
technology-innovative activities.
3
Biotechnopark KOLTSOVO
Cluster’s tasks:
•
•
•
to promote the production of
innovate drugs and substances
to increas the production of highquality affordable drugs – generic
drugs and dietary supplements
to prevent the threat to the
national security of Russia
The purpose of Biotechnopark
establishment:
•
•
to attract residents – investors
into the production of the final
forms of the pharmaceutical and
biotechnological products
to attract the enterprises which The establishment of Biotechnopark of the
Novosibirsk region is a part of formation and
are able to provide the
localization of the product
development of innovate territorial cluster
production cycle
“Biopharmaceutical Cluster of the Novosibirsk
region”
4
Investments and territory
The total investments for the
establishment of Biotechnopark
constituted EUR 11.4 million:
•EUR 5 million - from the regional budget
•More than EUR 500 thousand - from the
municipal budget
•About EUR 5.9 million from the funds of
private investors.
.Total planned area: about 114 hectares.
Two production platforms -14 and 100 hectares.
Development of infrastructure of the platform №1
allows disposing:
•research and production complex for production of
Trombovazim, unique materials for the production of
biologically active drugs of the next generation and
clinical nutrition,
•complex of medical products sterilization, manufacture
and modification of pharmaceutical substances with the
help of radiation techniques,
•other companies - residents.
The projecting of Center of Multiple Access for
biopharmaceutical companies is nearing completion at
the same platform.
Development of the platform № 2:
approximately two times increases the infrastructural
capacity of Koltsovo for placement of industrial
biotechnological and pharmaceutical facilities (by 100%
compared to the current level)
Ensures the effective placement of innovative industries
and businesses - large complex for deep grain
processing, plant for antibiotics and antioxidants
production, plant for production of biochips and other
5
industries.
Prospects of a
cluster ’s
development
•
The Russian pharmaceutical market will grow with the rates, advancing world
average growth rates
•
The accelerated development of the enterprises of pharmaceutical branch of the
region till 2016, in 2 times exceeding expected market average growth rates in
branch should become the purpose of carried-out actions within a created cluster
•
For pharmaceutical branch of the Russian Federation expected market average
growth rates in the long term are 12 -15 %. For the enterprises – cluster’s
participants target indicators are established at a level of 25 % of annual growth in
the long term till 2016-2017
6
Main types of production
in a cluster
•
•
•
•
•
•
•
The prolonged and immobilized forms of medicines
Mathematical methods of forecasting and modeling, database
(bioinformation technologies)
New drugs, medicine forms and delivery systems of active
ingredients, including protected by the patent
Innovative medicines and technologies
Equipment for medicine and biotechnology
Diagnostic aids (test systems)
Unique vaccines
18000 000
16000 000
Revenue of the
cluster’s enterprises
for the last 3 years
and a forecast for the
next years, one
thousand rub.
14000 000
12000 000
10000 000
8000 000
2009
2010
2011
2012
6000 000
4000 000
2000 000
0
2013
2014
2015
2016
Main actions for realization of target
reference points
•
In the sphere of production infrastructure:
1. address support to the enterprises–cluster’s participants
2. purposeful development of industrial platforms, production and social infrastructures in
interests of resident investors
•
In the sphere of researches, development and innovations:
1. creation of conditions for development of competitive researches and development
sectors
2. complex development of the innovative infrastructure providing technological possibility
of innovation introduction
•
In the higher education sphere:
1.ensuring innovative nature of education, formation of innovative thinking
2. participation of univercities in target preparation of demanded experts
It is planned:
Not less than 55 innovative projects by 2015
About two thousand high-tech workplaces
8
F
i
r
s
t
r
e
s
i
d
e
n
t
The Novosibirsk group of companies SCIENTIFIC FUTURE
MANAGEMENT has become first major Russian resident of
Biotechnopark with investments of more than RUB 2 billion which
now finishes the release of the drug TROMOVAZIM at this industrial
platform with the capacity to 1.5 million units per year.
TROMBOVAZIM is a
fundamentally new drug with a
strong thrombolytic and antiinflammatory action which is
produced in a capsules and
injections. It is used in the
treatment of chronic venous
insufficiency. TROMBOVAZIM
increases the fibrinolytic activity of
blood providing direct fibrinolytic
action. The drug has a trombolytic
effect which mechanism is
connected with the direct
destruction of fibrin forming the
basic molecular skeleton of
thrombus
9
THANKS FOR YOUR
ATTANTION!
10